NEW YORK (GenomeWeb News) – Decode Genetics said today that it has licensed three genetic markers for cardiovascular and metabolic diseases to Celera.

The markers may be used to create lab tests for individual risks of heart attack, stroke, atrial fibrillation, and type 2 diabetes, Decode said.

Under the agreement, Decode will receive an upfront payment and royalties from sales of testing products that use the markers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.